Clearstead Advisors, LLC Beam Therapeutics Inc. Transaction History
Clearstead Advisors, LLC
- $6.3 Billion
- Q1 2025
A detailed history of Clearstead Advisors, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 1,500 shares of BEAM stock, worth $23,745. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,500
Previous 1,518
1.19%
Holding current value
$23,745
Previous $37,000
21.62%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BEAM
# of Institutions
258Shares Held
93.6MCall Options Held
425KPut Options Held
309K-
Farallon Capital Management LLC San Francisco, CA9.93MShares$157 Million1.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.87MShares$140 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.48MShares$134 Million1.79% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$121 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$71.9 Million72.77% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.11B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...